PMV Pharmaceuticals, Inc.

PMV Pharmaceuticals, Inc. (PMVP) priced its initial public offering on Sep 25, 2020 at $18.00 per share, within its $16.00–$18.00 range, raising $211.8M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $774M. Goldman Sachs was lead-left underwriter, joined by BofA Securities, TD Cowen and Evercore ISI. Wilson Sonsini advised the company and Latham & Watkins advised the underwriters.

PMV Pharmaceuticals, Inc. is a precision oncology company developing small molecule, tumor-agnostic therapies that target p53 mutations, which occur in about half of all cancers. Its platform aims to structurally correct specific mutant p53 proteins and restore their normal tumor-suppressing function.

Status

IPO

Ticker

PMVP

Exchange

Nasdaq Global Select

Priced

Sep 25, 2020

IPO price

$18.00

Price range

$16.00–$18.00

Raised

$211.8M

Market cap at IPO price

$774M

First filed

Sep 4, 2020

Underwriters

Goldman Sachs, BofA Securities, TD Cowen and Evercore ISI

Company counsel

Wilson Sonsini

Underwriters' counsel

Latham & Watkins

Sector

Biotech & pharma

Country / state

NJ

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.